Stephens Inc. AR decreased its holdings in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 3.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 177,610 shares of the biopharmaceutical company’s stock after selling 5,904 shares during the quarter. Stephens Inc. AR’s holdings in Bristol-Myers Squibb were worth $9,896,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. State Street Corp lifted its stake in Bristol-Myers Squibb by 1.8% in the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock valued at $3,746,446,000 after acquiring an additional 1,223,457 shares during the last quarter. Jennison Associates LLC lifted its stake in Bristol-Myers Squibb by 5.4% in the second quarter. Jennison Associates LLC now owns 23,118,789 shares of the biopharmaceutical company’s stock valued at $1,288,179,000 after acquiring an additional 1,184,652 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Bristol-Myers Squibb by 18.7% in the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock valued at $845,504,000 after acquiring an additional 2,451,390 shares during the last quarter. Legal & General Group Plc lifted its stake in Bristol-Myers Squibb by 2.7% in the second quarter. Legal & General Group Plc now owns 8,431,348 shares of the biopharmaceutical company’s stock valued at $469,802,000 after acquiring an additional 217,920 shares during the last quarter. Finally, Swiss National Bank lifted its stake in Bristol-Myers Squibb by 3.2% in the second quarter. Swiss National Bank now owns 6,111,570 shares of the biopharmaceutical company’s stock valued at $340,537,000 after acquiring an additional 189,900 shares during the last quarter. Institutional investors and hedge funds own 69.69% of the company’s stock.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the sale, the senior vice president now owns 46,297 shares in the company, valued at approximately $2,777,820. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.23% of the company’s stock.

BMY has been the subject of a number of recent analyst reports. Vetr cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $63.81 price target for the company. in a research note on Wednesday, August 9th. Goldman Sachs Group reiterated a “buy” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. BidaskClub upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Cowen set a $65.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, August 14th. Finally, Credit Suisse Group set a $58.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Wednesday, August 16th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $64.93.

Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at $63.24 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. The stock has a market cap of $103,423.08, a PE ratio of 21.35, a PEG ratio of 2.40 and a beta of 1.18. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.77 EPS. research analysts forecast that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/12/02/stephens-inc-ar-sells-5904-shares-of-bristol-myers-squibb-company-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.